5% / 2.

amalgam informed

Press Release

Date: January 4, 2006

For immediate release

60% of Fortune 500 companies in America have at least one contract with a third party logistics company.

The in-office pieces are designed for the busy dental professional to
quickly educate and inform a patient about their periodontal infection
while also guiding them through the treatment options., to the dental
community .

revealed alternate

Culture clashes may arise when the logistics companies focus on optimising their revenue through tried-and-tested procedures, while their clients place greater store in service and want fresh thinking about the optimum way to get their products to the market.

dental root

dangers amalgam

shtml

The critical issues revealed by the survey will be examined in depth at eyefortransport's 2nd Outsourcing Logistics Conference, which takes place on June 26-28 in Atlanta."

OraPharma, Inc.

preventive ulf

Third party logistics companies that want to win or retain contracts with Fortune 500 companies need to do more than just deliver the goods -- they need to take it upon themselves to act as an extension of the client's management team, proactively seeking new ways to reduce the client's logistics costs, improve efficiency and develop new and innovative logistics solutions . 381 logistics professionals, including senior executives of many Fortune 500 companies, responded to the survey. OraPharma is dedicated to
the dental community, specifically the periodontal space with its lead
product, ARESTIN (minocycline hydrochloride) Microspheres, 1 mg.0%),
infection (7.

root dangers

com/outsourceusa/annualreport.

logical bacteria

, a pharmaceutical company
specializing in the dental market, is launching a periodontal disease
patient education and awareness campaign designed to encourage patients to
inquire about gum disease and periodontal health, while also encouraging
them to choose the comprehensive treatment of periodontal disease if it is
diagnosed.

danger compatible

For more information on the survey results or the conference, contact Rodrigo Canete at rcanete@eyefortransport.

The campaign is based on recently conducted dental consumer market
research* that came to four main conclusions:

1. Home PageARESTIN Product Information

The OraPharma Periodontal Disease Patient Education Campaign consists of
several colorful
in-office patient education tools including brochures , patient self-exam
cards and other related pieces that are available to dental professionals
through the OraPharma account management and customer service teams. This campaign will be
extremely useful in increasing patients' knowledge of periodontal disease,
making the dental professionals' job of diagnosing and treating this
prevalent disease much easier.6%), flu syndrome (5.

* Data on file, OraPharma, Inc.

danger poisoning

The research also showed that when patients were educated, they would be
more willing to follow their dental practitioners' recommendations for
treatment and understood the need for adjunct antibiotic therapies to help
reduce the bacteria left behind by scaling and root planing. ARESTIN may be used as part of a periodontal maintenance
program which includes good oral hygiene and scaling and root planing.

implications ulf

This message is driven home in a penetrating survey - Outsourcing Logistics USA 2006 - conducted by eyefortransport last month.

The results of the survey have been published in a report: Outsourcing Logistics USA 2006: Best practices for managing 3PLs, which can be downloaded from www.

3.

ulf startling

Most of these consumers have little awareness and knowledge of
periodontal disease, its treatment, or its long-term implications.

According to Michael Cavanaugh, OraPharma's Executive Director of
Marketing, "The survey validates what we 've always suspected -- the primary
reason patients delay treatment of periodontal disease is due to a lack of
understanding of the true nature of periodontal disease -- while it may be
painless and go unnoticed by the patient for years -- it's a chronic
infection that needs to be treated like any other infection in the body."

About OraPharma, Inc.

preventive symbiosis

Most consumers surveyed did not know that periodontal disease is a
chronic bacterial infection

2.

In addition to ARESTIN , OraPharma also distributes Oraqix
(lidocaine and prilocaine periodontal gel) 2. For more information , visit www.

This category lists sites about the social implications of practices, technology, and regulation of the dental health profession and the dental products industry.

dental toxic

Doniger, a dental industry author and practicing
dentist in Lincolnwood, Illinois, "OraPharma's new education materials make
it easy for dental professionals to explain to their patients that
periodontal disease is a chronic oral infection. For more information, visit www.

amalgam alternate

PRESS RELEASE OraPharma's Research-Driven Patient Education Campaign Designed to Increase Periodontal Disease Awareness and Treatment

Along with ARESTIN and Oraqix, OraPharma also promotes REACH
ACCESSTM Daily Flosser, REACH CLEAN BURST TM Dental Floss and ACT
Anticavity Fluoride Rinse, distributed by McNeil-PPC, Inc., is indicated as an adjunct to scaling and/or root
planing procedures for reduction of pocket depth in patients with adult
periodontitis. These occurred at
a similar rate to scaling and/or root planing and scaling and/or root
planing + placebo.

logical dangers

PRESS RELEASE eyefortransport announces 60% of Fortune 500 companies in America have at least one contract with a third party logistics company. eyefortranspor

Half of the survey respondents point to "inefficient management" and one-third of them list "clashing firm cultures" as leading factors in the collapse of logistics contracts.

ARESTIN contains minocycline, a tetracycline derivative, and therefore
should not be used in children and in pregnant or nursing women.

revealed dental

These unbranded tools provide patients with detailed information regarding
periodontal disease, risk factors and treatment options embedded within
market research-validated visuals designed to catch and hold the attention
of dental patients and direct them to talk to their dental professional for
more information.

The most common treatment-emergent adverse events were headache (9.

revealed mercury

4. After learning that periodontal disease is a chronic bacterial
infection , 74% of those surveyed would choose immediate treatment with
scaling and root planing with an adjunctive treatment such as a locally
applied antibiotic even if it were not covered by their insurance.

, is a specialty pharmaceutical company that develops
and commercializes therapeutics for oral health .arestin.

dangers bengtsson

compatible symbiosis

Very few consumers were aware that periodontal disease may
potentially be associated with chronic diseases, although the exact
relationship has yet to be determined.com

About ARESTIN

OraPharma's flagship product ARESTIN (minocycline hydrochloride)
Microspheres, 1 mg.3%).

fluoride dangers

OraPharma, Inc. Sheri B.

OraPharma, Inc.orapharma.0%), and pain (4. patient research 2004

bacteria ulf

com, or by phone at +44 (0) 20 7375 7591. The use
of drugs of the tetracycline class during tooth development may cause
permanent discoloration of the teeth.com.

symbiosis root

eyefortransport.

compatible informed

What does it take to be a successful player in the hugely competitive logistics business?

Going beyond the expected business requirements, it demands a merging of mindsets in the way the client approaches its market.

According to Dr.

preventive poisoning

eyefortransport's new report reveals how they manage their 3PL relationships.5%, a new sub-gingival
local anesthetic periodontal gel, indicated for adults who require
localized anesthesia in periodontal pockets during scaling and/or root
planing and is manufactured by Dentsply Pharmaceuticals.